Supreme Court Probes Legality of Post-Pandemic 'Emergency Use' Drug Licenses

New Delhi – The Supreme Court of India has initiated a significant judicial review into the regulatory framework governing drugs approved under emergency provisions, issuing a notice in a Public Interest Litigation (PIL) that challenges the continued manufacturing and sale of Liposomal Amphotericin B. The medication, a crucial antifungal drug, saw its production fast-tracked during the COVID-19 pandemic to treat secondary infections like mucormycosis.

The PIL, filed by petitioner Rajendra Prasad, contends that the "emergency use" authorizations granted to several leading pharmaceutical companies in 2021 have since expired, yet production continues without requisite regulatory oversight. A bench comprising Justices Vikram Nath and Sandeep Mehta has sought responses from the Union of India, the Drug Controller General of India (DCGI), and a roster of major pharmaceutical manufacturers, including Bharat Serum and Vaccines Ltd., Cipla, Sun Pharma, Emcure, and NATCO Pharma.

The case, titled RAJENDRA PRASAD Versus UNION OF INDIA AND ORS. , thrusts Section 26B of the Drugs and Cosmetics Act, 1940, into the judicial spotlight, questioning the temporal limits and post-emergency validity of licenses granted under its extraordinary powers.

The Core of the Challenge: Expired Authorizations and Regulatory Vacuum

The crux of the petitioner's argument, presented through Advocate on Record Tushar Giri, is that the legal foundation for the manufacturing of Liposomal Amphotericin B by the respondent companies has crumbled with the waning of the COVID-19 emergency. The PIL asserts that these companies are operating in a regulatory grey area.

"As per the petitioner, the medication continues to be manufactured by the respondent-companies on expired emergency authorizations which were granted in 2021 at the time of Covid-19 outbreak," the petition highlights.

This central claim raises profound questions about administrative law and statutory interpretation. The petition argues that authorizations granted under emergency powers are, by their very nature, temporary and contingent upon the existence of the emergency itself. The PIL suggests that with the formal cessation of the public health emergency, these licenses should have either been regularized through standard approval channels or been rescinded. The petitioner alleges that neither has occurred, resulting in a "regulatory vacuum" where a potent drug is manufactured and distributed without the stringent, multi-phase scrutiny typically required.

The specific reliefs sought by the petitioner are extensive and aim to dismantle the current production and supply chain:

• Production of Records: A directive to the Union of India and the DCGI to produce all records related to the approvals granted under Section 26B.
• Quashing of Licenses: The invalidation and quashing of all manufacturing licenses and permissions previously granted to the respondent companies for this drug.
• Cessation of Activities: An immediate stoppage of all manufacturing, distribution, and sale of the drug by these companies.
• Recall and Destruction: A comprehensive recall of existing market stock, followed by its seizure and destruction according to established safety protocols.

Legal Deep Dive: Section 26B and the Scope of Emergency Powers

At the heart of this litigation is Section 26B of the Drugs and Cosmetics Act, 1940. This provision empowers the Central Government to regulate, restrict, or prohibit the manufacture, sale, or distribution of any drug or cosmetic if it deems it necessary in the public interest or to address a public health emergency.

Section 26B: Power of Central Government to regulate or restrict, manufacture, etc., of drug and cosmetic in public interest. Without prejudice to any other provision contained in this Chapter, if the Central Government is satisfied, that a drug or cosmetic is essential to meet the requirements of an emergency arising due to epidemic or natural calamities and that in the public interest it is necessary or expedient so to do, then, that Government may, by notification in the Official Gazette, regulate or restrict the manufacture, sale or distribution of such drug or cosmetic.

During the COVID-19 pandemic, this section was invoked to expedite the availability of essential medicines like Liposomal Amphotericin B, which became critical in treating the surge of "black fungus" (mucormycosis) cases in recovering COVID-19 patients. The emergency provision allowed regulators to bypass certain standard, time-consuming approval procedures to meet an urgent public health need.

The current PIL forces a critical legal examination: Does an approval granted under Section 26B persist indefinitely, or is it implicitly time-bound by the duration of the emergency it was meant to address? The petitioner's stance is clear—the authority granted was temporary. The response from the Union Government and the DCGI will be pivotal in clarifying the official interpretation and administrative policy regarding the lifecycle of such emergency authorizations.

Broader Implications for the Pharmaceutical Industry and Public Health

The Supreme Court's decision to issue notice signals the judiciary's willingness to scrutinize the administrative actions taken during the pandemic and their ongoing consequences. The outcome of this case could establish a crucial precedent for the future of drug regulation in India.

1. Defining the Sunset Clause for Emergency Approvals: This case could compel the judiciary or the legislature to articulate a clear "sunset clause" for emergency use authorizations. If the court sides with the petitioner, it may establish that such approvals automatically lapse with the end of the declared emergency unless explicitly converted into a standard license through the complete regulatory process. This would bring much-needed clarity and prevent the indefinite continuation of emergency provisions.

2. Impact on Pharmaceutical Companies: For the respondent pharmaceutical giants, the stakes are high. An adverse ruling could lead to significant financial losses from the destruction of stock, the costs of recalling products, and the immediate halt of a revenue-generating production line. It could also trigger a review of other products that may have been brought to market under similar emergency provisions during the pandemic, potentially widening the scope of regulatory and legal challenges.

3. Strengthening Regulatory Oversight: The litigation underscores the vital role of continuous regulatory oversight. The petitioner's claim of a "regulatory vacuum" points to a potential gap in the post-emergency transition process. A favorable ruling for the petitioner would reinforce the DCGI's mandate to ensure all drugs in the market, regardless of their approval pathway, adhere to the highest standards of safety and efficacy, which includes re-evaluation after the exigencies of an emergency have passed.

4. Public Health and Safety: Ultimately, the case revolves around public health. While Liposomal Amphotericin B is an essential drug, the petitioner's argument is that its unchecked production outside the standard regulatory framework could pose risks. The PIL seeks to ensure that the systems designed to protect patients are not permanently weakened by emergency measures that have outlived their purpose.

As the Union of India, the DCGI, and the implicated pharmaceutical firms prepare their responses, the legal and healthcare communities will be watching closely. This case is more than a challenge to a single drug's license; it is a fundamental inquiry into the balance between regulatory agility in a crisis and the enduring principles of public safety and administrative accountability in its aftermath.